MONMOUTH JUNCTION, N.J., Jan. 3, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will give a corporate update and discuss goals for 2017 at the Biotech Showcase™ 2017 conference on Tuesday, January 10, 2017 at 8:30 AM PST in San Francisco, California. Dr. Chan will be joined by Kathleen Bloch, Chief Financial Officer, and Chris Cramer, Vice President of Business Development during the informal question and answer session that will follow.
Conference Presentation Details:
Where: Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA 94102
When: Tuesday, January 10, 2017 at 8:30 AM PST
Room: Room 3 – Ballroom Level
Conference Website: Biotech Showcase 2017
CytoSorbents' management will host one-on-one meetings with investors at the conference between January 9-12, 2017 but have limited availability due to other meetings. To meet with the Company, please contact Lea Garcia at [email protected] as soon as possible to schedule a meeting and also submit a meeting request via the PartneringOne scheduling system.
About Biotech Showcase™
Biotech Showcase™ 2017 is one of the industry's largest annual healthcare investor and partnering conferences, with more than 300 company presentations and 2,800+ attendees expected. Attendees include biopharmaceutical and life science company executives, investors in private and public companies, sector analysts, bankers and industry professionals. The conference is run concurrently with, but independently from, the JP Morgan Healthcare Conference in San Francisco, one of the largest and most influential international healthcare conferences.
Now in its ninth year, the Biotech Showcase™ features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy Colton Life Science Advisors and EBD Group.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 42 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial - a multi-center, randomized controlled study that has demonstrated the safety of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 17,000 human treatments to date.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $20 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Public Relations Contact:
SOURCE CytoSorbents Corporation